Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Dostarlimab monotherapy achieves strong clinical data from Phase II trial

Can Dostarlimab Replace Surgery for dMMR/MSI-H Rectal Cancer?

ByZachary Zubulake

July 13th 2026

A top view of medicine powders, liquids in containers, and various manufactured medicine on the American flag. An America pharmaceuticals concept. | image Credit: ©Ming -stock.adobe.com

The FDA Moves to Modernize Drug Manufacturing Registration

BySusan Haigney

July 10th 2026

Sarclisa Escena is subcutaneous injection designed for 3 multiple myeloma treatment combinations

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

ByZachary Zubulake

July 10th 2026

PharmTech Weekly Roundup–July 10, 2026

BySusan Haigney

July 10th 2026

Teva Pharmaceutical Industries and Polpharma Biologics Collab on Ocrevus (ocrelizumab)

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

ByZachary Zubulake

July 9th 2026

Analytical Methods Validation In-Process Control Methods for the Manufacture of Active Pharmaceutical Ingredients

Articles in this issue

Related Content

Can Dostarlimab Replace Surgery for dMMR/MSI-H Rectal Cancer?

The FDA Moves to Modernize Drug Manufacturing Registration

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma

PharmTech Weekly Roundup–July 10, 2026

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

Trending on Pharmaceutical Technology

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

The FDA Moves to Modernize Drug Manufacturing Registration

It’s Time to Build a More Scalable, Connected CRO

Structuring Tech Transfer for Optimized Collaboration

The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma